Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nonacog Alfa Deemed Safe and Effective in Hemophilia B

Key clinical point: Real-world data shows that the recombinant factor IX product nonacog alfa is safe and effective for patients with hemophilia B.

Major finding: Effectiveness rates were 95.5% and 93.7% for patients who received routine prophylaxis and on-demand treatment, respectively.

Study details: A postmarketing surveillance study of 312 patients with hemophilia B.

Disclosures: The study was funded and conducted by Pfizer Japan. The authors reported financial relationships with Pfizer and several other companies. One coauthor is an employee of Pfizer Japan.

Citation:

Fukutake K et al. Haemophilia. 2019 Jun 6. doi: 10.1111/hae.13783